Rheinische Friedrich-Wilhelms-Universität Bonn

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial (2022) Zeyen T, Potthoff AL, Nemeth R, Heiland DH, Burger MC, Steinbach JP, Hau P, et al. Journal article Reducing instability of inter-subject covariance of FDG uptake networks using structure-weighted sparse estimation approach (2022) Wang M, Schutte M, Grimmer T, Lizarraga A, Schultz T, Hedderich DM, Diehl-Schmid J, et al. Journal article Development of a high-rate scalable readout system for gaseous detectors (2022) Scharenberg L, Bortfeldt J, Brunbauer F, Christensen MJ, Desch K, Floethner K, Garcia F, et al. Journal article Chemoinformatics and artificial intelligence colloquium: progress and challenges in developing bioactive compounds (2022) Bajorath J, Chávez-Hernández AL, Duran-Frigola M, Fernández-de Gortari E, Gasteiger J, López-López E, Maggiora GM, et al. Journal article Dentate gyrus astrocytes exhibit layer-specific molecular, morphological and physiological features (2022) Karpf J, Unichenko P, Chalmers N, Beyer F, Wittmann MT, Schneider J, Fidan E, et al. Journal article A genome-wide association study with tissue transcriptomics identifies genetic drivers for classic bladder exstrophy (2022) Mingardo E, Beaman G, Grote P, Nordenskjöld A, Newman W, Woolf AS, Eckstein M, et al. Journal article German Registry for Cardiac Operations and Interventions in Patients with Congenital Heart Disease: Report 2021 and 9 Years' Longitudinal Observations on Fallot and Coarctation Patients (2022) Dittrich S, Arenz C, Krogmann O, Tengler A, Meyer R, Bauer U, Hofbeck M, et al. Journal article Aion is a bistable anion-conducting channelrhodopsin that provides temporally extended and reversible neuronal silencing (2022) Rodriguez-Rozada S, Wietek J, Tenedini F, Sauter K, Dhiman N, Hegemann P, Soba P, Wiegert JS Journal article The elegance of prickly sensations (2022) Imambocus BN, Soba P Journal article Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) (2022) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution